- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
NEJM: 15-year Osteoporosis Screening Gap OK for Many
Women with normal bone density are unlikely to develop osteoporosis within 15 years and can forego the duel-energy X-ray absorptiometry (DXA) radiology exams to detect it for at least that long.
Women with normal bone density are unlikely to develop osteoporosis within 15 years and can forego the duel-energy X-ray absorptiometry (DXA) radiology exams to detect it for at least that long, researchers reported online January 19 in the New England Journal of Medicine.
A team led by Margaret Gourlay, MD, MPH, of the University of North Carolina at Chapel Hill, tracked 4,957 women ages 67 and older for 15 years. The women had normal bone mineral density (BMD) or osteopenia (low BMD) and no history of hip or vertebra fracture, or treatment for osteoporosis. The aim was to provide a foundation for decisions about the interval between BMD tests.
The team defined an ideal BMD testing interval as the estimated time for 10 percent of women to make the transition to osteoporosis, but not yet break a hip or crack vertebrae.
Over the course of the study, 0.8 percent of women with normal BMD developed osteoporosis; among those with those with mild, moderate, and advanced osteopenia, 4.6 percent, 20.9 percent, and 62.3 percent developed it, respectively.
For women with normal BMD, the team established estimated testing intervals 16.8 years for women with normal BMD and 17.3 years for women with mild osteopenia. Women with moderate and advanced osteopenia would need more frequent testing, the team says - at 4.7 years and 1.1 years.
FDA Approves Fluorescence Imaging System for Detecting Residual Breast Cancer
April 18th 2024The combination of the optical imaging agent Lumisight and the fluorescence imaging device Lumicell Direct Visualization System, collectively known as LumiSystem, reportedly offers 84 percent accuracy with real-time detection of residual breast cancer after lumpectomy procedures.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.
Could a Deep Learning Model for Mammography Improve Prediction of DCIS and Invasive Breast Cancer?
April 15th 2024Artificial intelligence (AI) assessment of mammography images may significantly enhance the prediction of invasive breast cancer and ductal carcinoma in situ (DCIS) in women with breast cancer, according to new research presented at the Society for Breast Imaging (SBI) conference.
